Back to dashboard
CommercialCoverageMedium impact

08.02.25a, Fidanacogene elaparvovec-dzkt (Beqvez™)

Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

A new pharmacy policy for Fidanacogene elaparvovec-dzkt (Beqvez™) has been updated for commercial plans. This appears to be a gene therapy medication that will likely require specific coverage criteria and prior authorization requirements.

Action Required

Action needed
Immediately: Billing team should review the full policy details at the provided URL to understand coverage criteria and prior authorization requirements for Fidanacogene elaparvovec-dzkt (Beqvez™). Update billing system with appropriate HCPCS codes and coverage requirements once full policy details are obtained.

Related policy hubs